DSG2 and cardiomyopathy: Modulating inflammatory signaling pathways, such as NF-κB, may be a novel therapeutic target for desmosomal-mediated cardiomyopathy, as recently demonstrated in a mouse model harboring homozygous mutations in DSG2 (26).